Thor Halfdanarson, Professor of Oncology at Mayo Clinic School of Medicine, shared a post on X:
“TROP2 ADCs for lung NECs…? Why not?
In this study of patients with large cell lung NECs, 26% have ≥50% of cells positive for TROP2, especially if there was a NSCLC component. It looks like a trial may be needed here…”
Title: TROP2 immunoreactivity in pulmonary large cell neuroendocrine carcinoma
Authors: Michael Minkley, Kashif Ravasia, Thi Nghiem, Dongxia Gao, Jamie Feng, Andrew Churg, Julia R. Naso
Read the Full Article.
You can also read:
Could Proton Pump Inhibitors Affect Durvalumab Outcomes After Chemoradiotherapy in Stage III NSCLC?
